Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 2123 | 36.84 |
09:34 ET | 300 | 36.07 |
09:36 ET | 416 | 36.33 |
09:38 ET | 300 | 36.07 |
09:39 ET | 400 | 35.95 |
09:41 ET | 1000 | 36.25 |
09:43 ET | 100 | 36.315 |
09:45 ET | 1400 | 36.4 |
09:50 ET | 100 | 36.4 |
09:52 ET | 2466 | 36.535 |
09:54 ET | 900 | 36.66 |
09:57 ET | 511 | 36.63 |
09:59 ET | 600 | 36.54 |
10:01 ET | 100 | 36.44 |
10:03 ET | 2930 | 36.55 |
10:06 ET | 300 | 36.585 |
10:08 ET | 2470 | 36.47 |
10:10 ET | 200 | 36.385 |
10:12 ET | 1500 | 36.46 |
10:14 ET | 3100 | 36.5 |
10:15 ET | 8342 | 36.425 |
10:17 ET | 1951 | 36.5 |
10:19 ET | 13208 | 36.49 |
10:21 ET | 7701 | 36.47 |
10:24 ET | 2200 | 36.48 |
10:26 ET | 900 | 36.475 |
10:28 ET | 7869 | 36.49 |
10:30 ET | 2000 | 36.47 |
10:32 ET | 2812 | 36.48 |
10:33 ET | 2091 | 36.55 |
10:35 ET | 1000 | 36.565 |
10:37 ET | 1700 | 36.58 |
10:39 ET | 1556 | 36.6 |
10:42 ET | 900 | 36.57 |
10:44 ET | 500 | 36.57 |
10:46 ET | 1100 | 36.58 |
10:48 ET | 400 | 36.58 |
10:50 ET | 1400 | 36.565 |
10:51 ET | 1500 | 36.555 |
10:53 ET | 5780 | 36.56 |
10:55 ET | 1490 | 36.55 |
10:57 ET | 1100 | 36.54 |
11:00 ET | 900 | 36.54 |
11:02 ET | 3600 | 36.55 |
11:04 ET | 900 | 36.54 |
11:06 ET | 2991 | 36.64 |
11:08 ET | 500 | 36.57 |
11:09 ET | 1300 | 36.58 |
11:11 ET | 1080 | 36.57 |
11:13 ET | 2510 | 36.62 |
11:15 ET | 1286 | 36.67 |
11:18 ET | 2060 | 36.66 |
11:20 ET | 940 | 36.66 |
11:22 ET | 700 | 36.66 |
11:24 ET | 3363 | 36.655 |
11:26 ET | 1800 | 36.667 |
11:27 ET | 2316 | 36.69 |
11:29 ET | 1658 | 36.67 |
11:31 ET | 800 | 36.645 |
11:33 ET | 600 | 36.615 |
11:36 ET | 1040 | 36.63 |
11:38 ET | 300 | 36.605 |
11:40 ET | 1000 | 36.61 |
11:42 ET | 4296 | 36.595 |
11:44 ET | 600 | 36.61 |
11:45 ET | 1100 | 36.63 |
11:47 ET | 300 | 36.61 |
11:49 ET | 700 | 36.59 |
11:51 ET | 300 | 36.59 |
11:54 ET | 100 | 36.56 |
11:56 ET | 625 | 36.66 |
11:58 ET | 400 | 36.65 |
12:00 ET | 100 | 36.655 |
12:02 ET | 1521 | 36.7 |
12:03 ET | 100 | 36.77 |
12:05 ET | 200 | 36.785 |
12:07 ET | 500 | 36.78 |
12:09 ET | 300 | 36.78 |
12:12 ET | 930 | 36.99 |
12:14 ET | 100 | 36.99 |
12:16 ET | 400 | 36.995 |
12:18 ET | 400 | 36.99 |
12:20 ET | 1300 | 37.08 |
12:21 ET | 1550 | 37.045 |
12:23 ET | 1539 | 36.95 |
12:25 ET | 1300 | 36.94 |
12:27 ET | 400 | 36.935 |
12:30 ET | 400 | 36.945 |
12:32 ET | 300 | 36.95 |
12:34 ET | 1065 | 36.99 |
12:36 ET | 300 | 37 |
12:38 ET | 600 | 37.02 |
12:39 ET | 400 | 36.995 |
12:41 ET | 600 | 37.03 |
12:43 ET | 200 | 37.005 |
12:45 ET | 300 | 37.01 |
12:48 ET | 200 | 37.01 |
12:50 ET | 500 | 37.015 |
12:52 ET | 300 | 37.015 |
12:54 ET | 700 | 37.03 |
12:56 ET | 4506 | 37.02 |
12:57 ET | 120 | 37.04 |
12:59 ET | 300 | 37.04 |
01:01 ET | 3400 | 37.03 |
01:03 ET | 400 | 37.085 |
01:06 ET | 400 | 37.06 |
01:08 ET | 300 | 37.065 |
01:10 ET | 300 | 37.065 |
01:12 ET | 300 | 37.065 |
01:14 ET | 1687 | 37.005 |
01:15 ET | 200 | 37.005 |
01:17 ET | 1901 | 37 |
01:19 ET | 200 | 36.975 |
01:21 ET | 1248 | 37.03 |
01:24 ET | 400 | 37 |
01:26 ET | 300 | 36.995 |
01:28 ET | 400 | 36.995 |
01:30 ET | 1500 | 37.04 |
01:32 ET | 600 | 37.03 |
01:33 ET | 200 | 37.04 |
01:35 ET | 1356 | 37.06 |
01:37 ET | 914 | 37.035 |
01:39 ET | 600 | 37.035 |
01:42 ET | 600 | 37.05 |
01:44 ET | 900 | 37.05 |
01:46 ET | 1300 | 37.005 |
01:48 ET | 1000 | 37.08 |
01:50 ET | 400 | 37.04 |
01:51 ET | 200 | 37.03 |
01:53 ET | 500 | 37.045 |
01:55 ET | 300 | 37.04 |
01:57 ET | 800 | 37.025 |
02:00 ET | 400 | 37 |
02:02 ET | 800 | 36.99 |
02:04 ET | 600 | 36.975 |
02:06 ET | 1400 | 37.015 |
02:08 ET | 600 | 37 |
02:09 ET | 300 | 37.02 |
02:11 ET | 1400 | 37.05 |
02:13 ET | 668 | 37.075 |
02:15 ET | 1313 | 37.135 |
02:18 ET | 456 | 37.11 |
02:20 ET | 300 | 37.1 |
02:22 ET | 500 | 37.1 |
02:24 ET | 800 | 37.1 |
02:26 ET | 200 | 37.12 |
02:27 ET | 1402 | 37.13 |
02:29 ET | 600 | 37.13 |
02:31 ET | 400 | 37.13 |
02:33 ET | 1432 | 37.17 |
02:36 ET | 500 | 37.19 |
02:38 ET | 2162 | 37.205 |
02:40 ET | 400 | 37.185 |
02:42 ET | 1100 | 37.24 |
02:44 ET | 600 | 37.24 |
02:45 ET | 400 | 37.225 |
02:47 ET | 806 | 37.235 |
02:49 ET | 900 | 37.235 |
02:51 ET | 800 | 37.27 |
02:54 ET | 1000 | 37.26 |
02:58 ET | 200 | 37.26 |
03:00 ET | 300 | 37.27 |
03:02 ET | 600 | 37.255 |
03:03 ET | 1165 | 37.245 |
03:05 ET | 2795 | 37.235 |
03:07 ET | 400 | 37.23 |
03:09 ET | 3160 | 37.14 |
03:12 ET | 1600 | 36.995 |
03:14 ET | 100 | 36.99 |
03:16 ET | 3232 | 36.995 |
03:18 ET | 1981 | 37.06 |
03:20 ET | 1000 | 37.12 |
03:21 ET | 700 | 37.21 |
03:23 ET | 1862 | 37.26 |
03:25 ET | 800 | 37.29 |
03:27 ET | 1442 | 37.3 |
03:30 ET | 300 | 37.32 |
03:32 ET | 1100 | 37.34 |
03:34 ET | 600 | 37.36 |
03:36 ET | 1824 | 37.3 |
03:38 ET | 1100 | 37.305 |
03:39 ET | 300 | 37.34 |
03:41 ET | 3207 | 37.395 |
03:43 ET | 4556 | 37.4 |
03:45 ET | 1818 | 37.41 |
03:48 ET | 2597 | 37.415 |
03:50 ET | 4409 | 37.41 |
03:52 ET | 7860 | 37.3 |
03:54 ET | 2700 | 37.27 |
03:56 ET | 6579 | 37.24 |
03:57 ET | 5706 | 37.38 |
03:59 ET | 17632 | 37.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 2.8B | -13.8x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.3x | --- |
Geron Corp | 2.6B | -12.8x | --- |
MoonLake Immunotherapeutics | 2.6B | -55.6x | --- |
IDEAYA Biosciences Inc | 2.6B | -17.2x | --- |
Biohaven Ltd | 3.1B | -5.1x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.